Qiagen, Invitrogen Aggressive First-Half Acquirers | GenomeWeb

The first half of 2005 was marked by several major acquisitions by the companies in the BioCommerce Week Index. Qiagen and Invitrogen were the most aggressive in adding pieces to their businesses. Perhaps the most anticipated acquisition, however, was announced last week with Takara Bio inking an agreement to buy Becton Dickinson's Clontech unit (see article in this week's issue).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.